Secondary efficacy end points were the percentage changes from base - line in total proximal Fern BMD and 2 bone turnover markers-urinary type I collagen cross-linked N-telopeptide ( uNTx ) and serum bone-specific alkaline phosphatase ( sBAP ) - at 12 months and study end point .
